Department of Cardiology, Tel Aviv Medical Center, affiliated to Sackler School of Medicine, Tel Aviv, Israel.
EuroIntervention. 2018 Jul 20;14(4):e452-e458. doi: 10.4244/EIJ-D-18-00102.
The aim of this study was to evaluate the clinical efficacy of Coronary Sinus Reducer implantation in alleviating angina symptoms and improving objective ischaemia parameters and indices of physical capacity.
Patients with refractory angina (Canadian Cardiovascular Society [CCS] class 3-4) were treated with the Reducer. Baseline and follow-up evaluation consisted of clinical assessment including completion of the Seattle Angina Questionnaire (SAQ) and CCS class evaluation, and objective assessment by treadmill exercise test, dobutamine echocardiography and six-minute walk test (6MWT). Overall, 48 patients (40 male) were enrolled. No periprocedural or long-term adverse events were recorded. CCS class diminished from a mean of 3.4±0.5 at baseline to 2.0±1 (p<0.001), and all domains of the SAQ improved significantly following Reducer implantation. Mean exercise duration increased from 03:43±01:30 to 04:36±02:18 min:sec (p=0.025) and 6MWT distance increased from 299.9±97.9 m to 352.9±75.3 m (p=0.002). Ejection fraction (EF%) at stress increased from 51.0±10 to 56.5±10 (p=0.004), and wall motion score index improved from 1.58±0.4 to 1.37±0.3 (p=0.004).
Reducer implantation for the treatment of refractory angina is a simple and safe procedure which significantly alleviates symptoms of angina and improves objective ischaemia parameters and indices of physical function.
本研究旨在评估冠状窦减少器植入术缓解心绞痛症状、改善客观缺血参数和体力活动指标的临床疗效。
采用冠状窦减少器治疗难治性心绞痛(加拿大心血管学会[CCS]分级 3-4 级)患者。基线和随访评估包括临床评估,包括完成西雅图心绞痛问卷(SAQ)和 CCS 分级评估,以及跑步机运动试验、多巴酚丁胺超声心动图和 6 分钟步行试验(6MWT)的客观评估。共纳入 48 例患者(40 例男性)。无围手术期或长期不良事件发生。CCS 分级从基线时的 3.4±0.5 降至 2.0±1(p<0.001),SAQ 的所有领域在植入冠状窦减少器后均显著改善。运动时间从 03:43±01:30 增加到 04:36±02:18 分钟:秒(p=0.025),6MWT 距离从 299.9±97.9 米增加到 352.9±75.3 米(p=0.002)。应激时射血分数(EF%)从 51.0±10 增加到 56.5±10(p=0.004),壁运动评分指数从 1.58±0.4 改善至 1.37±0.3(p=0.004)。
冠状窦减少器植入术治疗难治性心绞痛是一种简单、安全的方法,可显著缓解心绞痛症状,改善客观缺血参数和体力活动指标。